FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-OMB Number: 0104 Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and A | J | Requiring S (Month/Day | 2. Date of Event Requiring Statement (Month/Day/Year) 10/18/2023 3. Issuer Name and Ticker or Trading Symbol Eiger BioPharmaceuticals, Inc. [EIGR] | | | | | | | | |
|--|---------|---------------------------|---|--|--|------------------------|--|--|---|----------------------------|--|
| (Last) (First) (Middle) 1900 AVENUE OF THE STARS, | | | | | 4. Relationship of Reporting Issuer (Check all applicable) | , | · · · | | 5. If Amendment, Date of Original Filed (Month/Day/Year) | | |
| #1000 (Street) | | | | | Director Officer (give title below) | Other | 10% Owner Other (specify below) | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | |
| LOS ANGELES | CA | 90067 | | | | | | | Form filed Reporting I | by More than One Person | |
| (City) | (State) | (Zip) | | | | | | | | | |
| Table I - Non-Derivative Securities Beneficially Owned | | | | | | | | | | | |
| 1. Title of Security (Instr. 4) | | | | | 2. Amount of Securities Beneficially Owned (Instr. I) | Form: I (D) or I | | | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | |
| Common Stock | | | | | 1,667,100 | I | | See footnote. (1)(4) | | | |
| Common Stock | | | | | 2,700,000 I | | See footnote. (2)(4) | | | | |
| Common Stock | | | | | 729,886 | I | | See footnote. (3)(4) | | | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable an Expiration Date (Month/Day/Year) | | | ate | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Convers or Exerc | | cise | 5. Ownership Form: Direct (D) | 6. Nature of Indirect Beneficial Ownership (Instr. | | | |
| | | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Derivative Security | | or Indirect (I) (Instr. 5) | 5) | | |

Explanation of Responses:

- 1. Mr. Kayne shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Mr. Kayne and Propel General Partner act as the general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds directly own 1,667,100 shares of Common
- 2. Mr. Kayne provides discretionary advisory services to an investment company registered under the Investment Company Act of 1940, as amended, and such investment company directly owns 2,700,000 shares of Common Stock.
- 3. Mr. Kayne is the trustee and beneficiary of the Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999, a California trust (the "Family Trust"), and The Family Trust directly owns 729,886 shares of Common Stock.
- 4. Mr. Kayne expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.

10/30/2023 /s/ Richard A. Kayne ** Signature of Reporting Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB